论文部分内容阅读
采用ＲＴ－ＰＣＲ和ＭＴＴ吸收光度法对３５例卵巢癌分别检测组织中的ＭＤＲ１基因表达和对常用化疗药物的敏感性，并对其与临床近期疗效关系分析。结果：①癌组织中ＭＤＲ１阳性表达率为５７．１％，体外药敏细胞毒性与药物浓度呈正相关。均与临床分期和病理类型无关；②ＭＤＲ１表达阳性的癌组织对化疗药物敏感的平均数量低于ＭＤＲ１表达阴性者，大部分为ＡＤＭ、ＭＭＣ、ＣＴＸ和ＶＣＲ敏感性降低，而ＤＤＰ、ＣＰ、５－Ｆｕ的敏感性与ＭＤＲ１表达与否无明显相关；③ＭＤＲ１表达阳性和阴性的患者对化疗的有效率分别为４５．０％和７３．３％，对ＭＤＲ１表达阳性的患者根据体外药敏试验选择化疗方案，近期疗效也优于盲目化疗者。结果提示：癌组织中ＭＤＲ１的表达与部分化疗药物的体外敏感性有关，ＭＤＲ１的表达检测对临床判断化疗敏感性有一定价值。对耐药患者采用药敏方案治疗有助于提高疗效。
35 cases of ovarian cancer were examined by RT-PCR and MTT absorption spectrophotometry for detecting the expression of MDR1 gene and the sensitivity to commonly used chemotherapeutic drugs. The relationship between the MDR1 gene expression and clinical efficacy was also analyzed. Results: ① The positive rate of MDR1 in cancer tissues was 57.1%. The drug-sensitive cytotoxicity in vitro was positively correlated with drug concentration. (P <0.05); (2) The average number of MDR1-positive cancer tissues was less sensitive to chemotherapeutic drugs than those with negative MDR1 expression, most of them were decreased in sensitivity to ADM, MMC, CTX and VCR, while the expression of DDP, Fu sensitivity and MDR1 expression was not significantly correlated; ③MDR1 positive and negative expression of chemotherapy in patients with effective rates were 45.0% and 73.3%, MDR1-positive patients selected according to in vitro susceptibility testing of chemotherapy Program, the recent efficacy is better than blind chemotherapy. The results suggest that the expression of MDR1 in cancer tissues is related to the in vitro sensitivity of some chemotherapeutic drugs. The detection of MDR1 expression has some value in clinical judgment of chemosensitivity. Drug-resistant patients with drug-sensitive treatment program will help to improve the curative effect.